US$ 25.36
igf-1 lr3 long term use Recombinant Human IGF-I/IGF-1 GMP Protein, CF 8335D-GMP: R&D Systems IGF-1 LR3 Peptide Therapy in
Description
Clinics following evidence-based protocols typically administer 600 mg to 1200 mg once or twice weekly for 812 weeks, then taper to maintenance

Rely on the brand's official site for current information before ordering

doi: 10.3389/fendo.2023.1133000 Received 28 December 2022 Accepted 13 March 2023 Published 24 March 2023 Volume 14 - 2023 Edited by Silvia Martina Ferrari, University of Pisa, Italy Reviewed by Sabrina Rosaria Paparo, University of Pisa, Italy

T.LaFauciG.WegielJ.et al (2013)

doi: 10.1016/j.micpath.2016.06.008
